Aliases & Classifications for Dengue Shock Syndrome

MalaCards integrated aliases for Dengue Shock Syndrome:

Name: Dengue Shock Syndrome 12 55 15 73
Dss 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0050125
UMLS 73 C0376300

Summaries for Dengue Shock Syndrome

Disease Ontology : 12 A dengue disease that involves the most severe form of dengue fever, has material basis in Dengue virus [NCBITaxon:12637] with four serotypes (Dengue virus 1, 2, 3 and 4), which are transmitted by Aedes mosquito bite. The infection has symptom easy bruising, has symptom blood spots, has symptom bleeding gums, and has symptom nosebleeds. It is accompanied by circulatory collapse, involves hypotension, narrow pulse pressure (less than or equal to 20mm Hg), or frank shock. The shock occurs after two to six days of symptoms, followed by collapse, weak pulse, and blueness around the mouth.

MalaCards based summary : Dengue Shock Syndrome, also known as dss, is related to dengue hemorrhagic fever and acute respiratory distress syndrome, and has symptoms including easy bruising, blood spots and bleeding gums. An important gene associated with Dengue Shock Syndrome is THBD (Thrombomodulin), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Influenza A. The drugs Histamine and Ketotifen have been mentioned in the context of this disorder. Affiliated tissues include testes, endothelial and heart.

Related Diseases for Dengue Shock Syndrome

Diseases related to Dengue Shock Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 205)
# Related Disease Score Top Affiliating Genes
1 dengue hemorrhagic fever 29.9 CMA1 HLA-A IL6 TNF
2 acute respiratory distress syndrome 29.9 IL1B IL6 TNF
3 peritonitis 28.4 CCL2 IL1B IL6 TNF
4 malaria 26.1 CCL2 HLA-A IL1B IL1RN IL6 THBD
5 dengue disease 12.1
6 dengue virus 11.5
7 cutaneous mastocytosis 10.7 CMA1 TPSAB1
8 systemic onset juvenile idiopathic arthritis 10.7 IL1B TNF
9 gastric cancer, hereditary diffuse 10.6 IL1B IL1RN
10 staphylococcal toxic shock syndrome 10.6 IL1B TNF
11 schnitzler syndrome 10.6 IL1B IL1RN
12 autoimmune myocarditis 10.6 IL1B TNF
13 kashin-beck disease 10.6 IL1B TNF
14 recurrent corneal erosion 10.6 IL1B IL6
15 bagassosis 10.6 IL1B IL6
16 periodontitis, chronic 10.6 IL1B IL6
17 burns 10.6 IL1B TNF
18 cryopyrin-associated periodic syndrome 10.5 IL1RN IL6
19 scorpion envenomation 10.5 IL6 TNF
20 acute cholangitis 10.5 IL1RN IL6
21 haemophilus influenzae 10.5 IL1B TNF
22 leukomalacia 10.5 IL6 TNF
23 uremic pruritus 10.5 IL1B IL6
24 angioimmunoblastic lymphadenopathy with dysproteinemia 10.5 IL6 TNF
25 funisitis 10.5 IL1B IL6
26 glossitis 10.5 IL1B IL6
27 retinitis pigmentosa 60 10.5 IL1B TNF
28 euthyroid sick syndrome 10.5 IL1B IL6
29 critical limb ischemia 10.5 IL6 TNF
30 streptococcal toxic-shock syndrome 10.5 IL6 TNF
31 irritant dermatitis 10.5 IL1B TNF
32 null-cell leukemia 10.4 IL6 TNF
33 hemorrhagic fever 10.4
34 actinic prurigo 10.4 IL1B TNF
35 ascaris lumbricoides infection 10.4 IL1B IL6
36 retinitis pigmentosa 55 10.4 IL6 TNF
37 anca-associated vasculitis 10.4 IL6 TNF
38 crohn's colitis 10.4 IL1B TNF
39 meningococcemia 10.4 IL1B IL1RN THBD
40 vulvar vestibulitis syndrome 10.3 IL1B IL1RN TNF
41 cerebral artery occlusion 10.3 IL1B IL1RN TNF
42 aseptic meningitis 10.3 IL1B IL1RN TNF
43 peptic ulcer disease 10.3 IL1B IL1RN TNF
44 periapical periodontitis 10.3 IL1B IL6
45 duodenal ulcer 10.3 IL1B IL1RN TNF
46 familial mediterranean fever 10.3 IL1B IL1RN TNF
47 posterior urethral valves 10.3 IL6 TNF
48 helicobacter pylori infection 10.3 IL1B IL1RN TNF
49 hydrarthrosis 10.3 IL1B IL1RN IL6
50 end stage renal failure 10.2 IL6 PLCE1 TNF

Graphical network of the top 20 diseases related to Dengue Shock Syndrome:



Diseases related to Dengue Shock Syndrome

Symptoms & Phenotypes for Dengue Shock Syndrome

Symptoms:

12
  • easy bruising
  • blood spots
  • bleeding gums
  • nosebleeds

Drugs & Therapeutics for Dengue Shock Syndrome

Drugs for Dengue Shock Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 35)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Histamine Approved, Investigational Phase 4 75614-87-8, 51-45-6 774
2
Ketotifen Approved Phase 4 34580-14-8, 34580-13-7 3827
3 Anti-Allergic Agents Phase 4
4 Antipruritics Phase 4
5 Dermatologic Agents Phase 4
6 Histamine Antagonists Phase 4
7 Histamine H1 Antagonists Phase 4
8
Histamine Phosphate Phase 4 51-74-1 65513
9 Neurotransmitter Agents Phase 4
10
Ivermectin Approved, Investigational, Vet_approved Phase 2, Phase 3 70288-86-7 6474909
11 Pharmaceutical Solutions Phase 3,Phase 2
12 Anti-Infective Agents Phase 2, Phase 3
13 Antiparasitic Agents Phase 2, Phase 3
14 Vaccines Phase 3,Phase 2,Phase 1,Not Applicable
15 Heptavalent Pneumococcal Conjugate Vaccine Phase 3,Phase 2
16
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
17
Ribavirin Approved Phase 2 36791-04-5 37542
18
Neomycin Approved, Vet_approved Phase 1, Phase 2 1404-04-2 8378
19 Antimetabolites Phase 2
20 Antiviral Agents Phase 2
21 Cortisol succinate Phase 2
22 Hydrocortisone 17-butyrate 21-propionate Phase 2
23 Hydrocortisone acetate Phase 2
24 Antibodies Phase 1, Phase 2,Phase 2
25 Immunoglobulins Phase 1, Phase 2,Phase 2
26
Aluminum hydroxide Approved, Investigational Phase 1 21645-51-2
27
Aluminum sulfate Approved Phase 1 10043-01-3
28 Adjuvants, Immunologic Phase 1
29 Antacids Phase 1
30 Anti-Ulcer Agents Phase 1
31 Gastrointestinal Agents Phase 1
32
Permethrin Approved, Investigational Not Applicable 52645-53-1 40326
33 gamma-Globulins Not Applicable
34 Immunoglobulins, Intravenous Not Applicable
35 Rho(D) Immune Globulin Not Applicable

Interventional clinical trials:

(show top 50) (show all 103)
# Name Status NCT ID Phase Drugs
1 Ketotifen as a Treatment for Vascular Leakage During Dengue Fever Unknown status NCT02673840 Phase 4 Ketotifen;Placebo
2 Effect of Hypertonic Sodium Lactate on sVCAM-1 Level as Surrogate Marker of Endothelial Capillary Leakage in Pediatric Dengue Shock Syndrome Patients (DSS) Unknown status NCT00966628 Phase 3 Hypertonic sodium lactate;Ringer's lactate
3 Efficacy and Safety of Ivermectin Against Dengue Infection Unknown status NCT02045069 Phase 2, Phase 3 2 days Ivermectin;3 days Ivermectin;Placebo
4 Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia Unknown status NCT01373281 Phase 3
5 Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America Unknown status NCT01374516 Phase 3
6 Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia Completed NCT01254422 Phase 3
7 Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia Completed NCT01134263 Phase 3
8 Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers Completed NCT01411241 Phase 3
9 Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers Completed NCT01436396 Phase 3
10 Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects Active, not recruiting NCT02992418 Phase 3
11 Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Active, not recruiting NCT02747927 Phase 3 TDV Placebo
12 Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue Active, not recruiting NCT03423173 Phase 3
13 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil® Active, not recruiting NCT02993757 Phase 3
14 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® Active, not recruiting NCT02979535 Phase 3
15 Chinese and Western Medicine Treatment of Fever Associated With Bleeding Symptoms Unknown status NCT01973855 Phase 2 Western Medicine;TCM and Western Medicine
16 Celgosivir as a Treatment Against Dengue Completed NCT01619969 Phase 1, Phase 2 celgosivir;placebo
17 A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines Completed NCT01064141 Phase 2
18 Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US Completed NCT00617344 Phase 2
19 Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America Completed NCT01187433 Phase 2
20 Safety and Immunogenicity With Two Different Serotype 2 Potencies of Tetravalent Dengue Vaccine (TDV) in Adults in Singapore Completed NCT02425098 Phase 2
21 Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) Completed NCT02193087 Phase 2 TDV Liquid Formulation 1;TDV Liquid Formulation 2;TDV IDT Lyophilized;Placebo
22 A Phase I/II Trial of a Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naïve Children Completed NCT00384670 Phase 1, Phase 2
23 Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India Completed NCT01550289 Phase 2
24 A Study of Two Doses of WRAIR Dengue Vaccine Administered Six Months Apart to Healthy Adults and Children Completed NCT00468858 Phase 2
25 Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine Completed NCT01943825 Phase 2
26 Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults Completed NCT00740155 Phase 2
27 Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects Completed NCT00730288 Phase 2
28 Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine Completed NCT01488890 Phase 2
29 Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore Completed NCT00880893 Phase 2
30 Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects Completed NCT00875524 Phase 2
31 Efficacy and Safety of Dengue Vaccine in Healthy Children Completed NCT00842530 Phase 2
32 Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years Completed NCT00788151 Phase 2
33 Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America Completed NCT00993447 Phase 2
34 A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants Completed NCT00322049 Phase 1, Phase 2
35 Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years Completed NCT01511250 Phase 2
36 VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents Recruiting NCT03110770 Phase 2
37 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule Active, not recruiting NCT02824198 Phase 2
38 Immunogenicity and Safety of 3-Dose and Booster Dose of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age Active, not recruiting NCT02628444 Phase 2
39 Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule Active, not recruiting NCT02623725 Phase 2
40 Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Participants Active, not recruiting NCT02302066 Phase 2 TDV Placebo
41 Celgosivir or Modipafant as Treatment for Adult Participants With Uncomplicated Dengue Fever in Singapore Not yet recruiting NCT02569827 Phase 1, Phase 2 Celgosivir;Modipafant 50mg;Placebo;Modipafant 100mg
42 Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults Not yet recruiting NCT02741128 Phase 2
43 Pharmacokinetics and Pharmacodynamics of Ivermectin in Pediatric Dengue Patients Not yet recruiting NCT03432442 Phase 2 Ivermectin
44 A Study of Balapiravir in Patients With Dengue Virus Infection Completed NCT01096576 Phase 1 balapiravir [RO4588161];placebo
45 Safety and Immunogenicity Study to Assess TDV, a Live Attenuated Tetravalent Vaccine for Prevention of Dengue Fever Completed NCT01224639 Phase 1
46 Safety of and Immune Response to Two Different Dengue Virus Vaccines in Individuals Previously Immunized Against Dengue Virus Completed NCT00458120 Phase 1
47 Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3delta30/31‐7164) in Healthy Adults Completed NCT00831012 Phase 1
48 Safety Study of a Vaccine (DENV-1 PIV) to Prevent Dengue Disease Completed NCT01502735 Phase 1
49 Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-200,201) in Healthy Adults Completed NCT00270699 Phase 1
50 Safety of and Immune Response to a Dengue Virus Vaccine (rDEN2/4delta30[ME]) in Healthy Adults Completed NCT00094705 Phase 1

Search NIH Clinical Center for Dengue Shock Syndrome

Genetic Tests for Dengue Shock Syndrome

Anatomical Context for Dengue Shock Syndrome

MalaCards organs/tissues related to Dengue Shock Syndrome:

41
Testes, Endothelial, Heart, Liver, Bone, T Cells, Whole Blood

Publications for Dengue Shock Syndrome

Articles related to Dengue Shock Syndrome:

(show top 50) (show all 138)
# Title Authors Year
1
Joint ancestry and association test indicate two distinct pathogenic pathways involved in classical dengue fever and dengue shock syndrome. ( 29447178 )
2018
2
Vitamin D serostatus and dengue fever progression to dengue hemorrhagic fever/dengue shock syndrome. ( 28903788 )
2017
3
Skin dendritic cell and T cell activation associated with dengue shock syndrome. ( 29079750 )
2017
4
Dengue shock syndrome with retroperitoneal haematoma requiring repeated artery angioembolization. ( 28889142 )
2017
5
The value of daily platelet counts for predicting dengue shock syndrome: Results from a prospective observational study of 2301 Vietnamese children with dengue. ( 28448490 )
2017
6
Corrigendum to "Does Comorbidity Increase the Risk of Dengue Hemorrhagic Fever and Dengue Shock Syndrome?" ( 29360109 )
2017
7
Dengue shock syndrome. ( 28031845 )
2016
8
In silico transcriptional regulation and functional analysis of dengue shock syndrome associated SNPs in PLCE1 and MICB genes. ( 27038471 )
2016
9
Clinical Characteristics and Risk Factors of Dengue Shock Syndrome in Children. ( 27455442 )
2016
10
Delayed subdural hematoma after recovery from dengue shock syndrome. ( 27114678 )
2016
11
State-of-the-art monitoring in treatment of dengue shock syndrome: a case series. ( 27553703 )
2016
12
Fatal invasive aspergillosis: a rare co-infection with an unexpected image presentation in a patient with dengue shock syndrome. ( 26072955 )
2015
13
A Prognostic Model for Development of Profound Shock among Children Presenting with Dengue Shock Syndrome. ( 25946113 )
2015
14
Dengue haemorrhagic fever or dengue shock syndrome in children. ( 25860404 )
2015
15
Alpha tryptase allele of Tryptase 1 (TPSAB1) gene associated with Dengue Hemorrhagic Fever (DHF) and Dengue Shock Syndrome (DSS) in Vietnam and Philippines. ( 25797204 )
2015
16
Corticosteroids in the treatment of dengue shock syndrome. ( 24899817 )
2014
17
Early resuscitation of Dengue Shock Syndrome in children with hyperosmolar sodium-lactate: a randomized single blind clinical trial of efficacy and safety. ( 25189175 )
2014
18
Dengue shock syndrome in an infant. ( 25073530 )
2014
19
A replication study confirms the association of GWAS-identified SNPs at MICB and PLCE1 in Thai patients with dengue shock syndrome. ( 24884822 )
2014
20
Association of IL1B -31C/T and IL1RA variable number of an 86-bp tandem repeat with dengue shock syndrome in Thailand. ( 24446526 )
2014
21
Dengue Shock Syndrome or Dehydration? The importance of considering clinical severity when classifying patients with dengue. ( 24403543 )
2014
22
Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. ( 23471635 )
2013
23
Possible cause of liver failure in patient with dengue shock syndrome. ( 23763890 )
2013
24
Clinical characteristics of dengue shock syndrome in Vietnamese children: a 10-year prospective study in a single hospital. ( 24046311 )
2013
25
Differences in clinical features between children and adults with dengue hemorrhagic fever/dengue shock syndrome. ( 24437312 )
2013
26
Factors associated with dengue shock syndrome: a systematic review and meta-analysis. ( 24086778 )
2013
27
A patient with severe body aches without fever progressing to dengue shock syndrome. ( 24385064 )
2013
28
Serological characterization of dengue virus infections observed among dengue hemorrhagic fever/dengue shock syndrome cases in upper Myanmar. ( 23595687 )
2013
29
Role of cognitive parameters in dengue hemorrhagic fever and dengue shock syndrome. ( 24305068 )
2013
30
Sympathetic dysfunction as a cause for hypotension in dengue shock syndrome. ( 23075741 )
2012
31
Splenic rupture mimicking dengue shock syndrome. ( 23025068 )
2012
32
Repeated dengue shock syndrome and 'dengue myocarditis' responding dramatically to a single dose of methyl prednisolone. ( 22521778 )
2012
33
A fatal combo of dengue shock syndrome with acute subdural hematoma. ( 22406795 )
2012
34
A fatal case of bone marrow embolism of unknown cause masquerading clinically as dengue shock syndrome. ( 23455811 )
2012
35
Dengue shock syndrome with two atypical complications. ( 21842280 )
2012
36
Association of mast cell-derived VEGF and proteases in Dengue shock syndrome. ( 22363824 )
2012
37
Peritoneal dialysis in dengue shock syndrome may be detrimental. ( 22529870 )
2012
38
Phenotypic characterization of patient dengue virus isolates in BALB/c mice differentiates dengue fever and dengue hemorrhagic fever from dengue shock syndrome. ( 21835036 )
2011
39
Infection-associated hemophagocytic syndrome among patients with dengue shock syndrome and invasive aspergillosis: a case series and review of the literature. ( 22299436 )
2011
40
Characterization of dengue shock syndrome in pediatric patients in El Salvador. ( 21490492 )
2011
41
Risk factors of dengue shock syndrome in children. ( 21367851 )
2011
42
Phenotypic and genotypic characterization of dengue virus isolates differentiates dengue fever and dengue hemorrhagic fever from dengue shock syndrome. ( 21922323 )
2011
43
Genome-wide association study identifies susceptibility loci for dengue shock syndrome at MICB and PLCE1. ( 22001756 )
2011
44
Dengue shock syndrome at the emergency room of Queen Sirikit National Institute of Child Health, Bangkok, Thailand. ( 22043755 )
2011
45
Effect of a single dose of methyl prednisolone as rescue medication for patients who develop hypotensive dengue shock syndrome during the febrile phase: a retrospective observational study. ( 21530348 )
2011
46
National guidelines for diagnosis and management of dengue fever/dengue haemorrhagic fever and dengue shock syndrome. ( 21888156 )
2011
47
Should colloid boluses be prioritized over crystalloid boluses for the management of dengue shock syndrome in the presence of ascites and pleural effusions? ( 21356095 )
2011
48
Epidemiological factors associated with dengue shock syndrome and mortality in hospitalized dengue patients in Ho Chi Minh City, Vietnam. ( 21212214 )
2011
49
Genome-wide expression profiling deciphers host responses altered during dengue shock syndrome and reveals the role of innate immunity in severe dengue. ( 20652028 )
2010
50
The early whole-blood transcriptional signature of dengue virus and features associated with progression to dengue shock syndrome in Vietnamese children and young adults. ( 20943967 )
2010

Variations for Dengue Shock Syndrome

Expression for Dengue Shock Syndrome

Search GEO for disease gene expression data for Dengue Shock Syndrome.

Pathways for Dengue Shock Syndrome

Pathways related to Dengue Shock Syndrome according to GeneCards Suite gene sharing:

(show all 41)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.25 CCL2 HLA-A IL1B IL1RN IL6 TNF
2
Show member pathways
12.7 CCL2 HLA-A IL1B IL6 TNF
3
Show member pathways
12.53 HLA-A IL1B IL6 TNF
4
Show member pathways
12.5 CCL2 IL1B IL6 TNF
5
Show member pathways
12.48 HLA-A IL6 MICB TNF
6 12.47 CCL2 IL1B IL1RN TNF
7
Show member pathways
12.26 CCL2 IL1B IL6 TNF
8
Show member pathways
12.25 CCL2 IL1B IL6 TNF
9
Show member pathways
12.16 IL1B IL6 TNF
10
Show member pathways
12.14 IL1B IL1RN IL6 TNF
11 12.09 IL1B IL1RN IL6 TNF
12
Show member pathways
12.08 IL1B IL6 TNF
13 11.98 CCL2 IL1B THBD TNF
14 11.86 CCL2 IL1B IL6 TNF
15
Show member pathways
11.82 CMA1 TNF TPSAB1
16 11.81 IL1B IL6 TNF
17 11.81 CCL2 IL1B IL6 TNF
18 11.8 IL1B IL6 TNF
19 11.77 CCL2 IL1B IL6 TNF
20 11.69 IL1B IL6 TNF
21 11.66 CCL2 IL1B IL6 TNF
22
Show member pathways
11.6 IL1B IL6 TNF
23 11.52 IL1B IL6 TNF
24 11.49 IL1B IL6 THBD TNF
25 11.46 CCL2 IL1B TNF
26 11.41 IL1B IL6 TNF
27 11.35 CCL2 CMA1 IL1B IL6 TNF
28 11.29 IL1B IL6 TNF
29 11.28 IL1B IL6 TNF
30 11.26 CCL2 IL6 THBD
31 11.25 CCL2 IL1B IL6 TNF
32 11.21 IL1B IL6 TNF
33 11.18 IL1B IL6 TNF
34 11.15 IL1B IL6 TNF
35 11.1 CCL2 IL1B IL6 PLCE1 THBD TNF
36 11.08 CCL2 IL1B
37 11.04 CCL2 IL1B IL1RN IL6 TNF
38 11.02 IL1B TNF
39 11.01 IL6 TNF
40 10.95 IL6 TNF
41 10.75 CCL2 IL1B TNF

GO Terms for Dengue Shock Syndrome

Cellular components related to Dengue Shock Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.5 CCL2 CMA1 IL1B IL1RN IL6 TNF
2 extracellular space GO:0005615 9.23 CCL2 CMA1 IL1B IL1RN IL6 THBD

Biological processes related to Dengue Shock Syndrome according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.83 CCL2 IL1B IL1RN IL6 TNF
2 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.8 IL1B IL6 TNF
3 cellular response to lipopolysaccharide GO:0071222 9.79 CCL2 IL6 TNF
4 activation of MAPK activity GO:0000187 9.77 IL1B PLCE1 TNF
5 positive regulation of DNA binding transcription factor activity GO:0051091 9.77 IL1B IL6 TNF
6 cellular response to organic cyclic compound GO:0071407 9.73 CCL2 IL1B TNF
7 inflammatory response GO:0006954 9.72 CCL2 IL1B IL1RN IL6 TNF
8 response to glucocorticoid GO:0051384 9.71 IL1RN IL6 TNF
9 humoral immune response GO:0006959 9.7 CCL2 IL6 TNF
10 positive regulation of interleukin-6 production GO:0032755 9.63 IL1B IL6 TNF
11 positive regulation of chemokine production GO:0032722 9.62 IL6 TNF
12 negative regulation of lipid catabolic process GO:0050995 9.61 IL1B TNF
13 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.61 IL1B TNF
14 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.58 IL1B TNF
15 negative regulation of lipid storage GO:0010888 9.58 IL6 TNF
16 positive regulation of chemokine biosynthetic process GO:0045080 9.57 IL1B TNF
17 regulation of establishment of endothelial barrier GO:1903140 9.55 IL1B TNF
18 protein kinase B signaling GO:0043491 9.54 CCL2 IL1B TNF
19 positive regulation of fever generation GO:0031622 9.51 IL1B TNF
20 fever generation GO:0001660 9.49 IL1B IL1RN
21 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.48 IL1RN IL6
22 sequestering of triglyceride GO:0030730 9.4 IL1B TNF
23 cytokine-mediated signaling pathway GO:0019221 9.35 CCL2 IL1B IL1RN IL6 TNF
24 lipopolysaccharide-mediated signaling pathway GO:0031663 9.33 CCL2 IL1B TNF
25 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.26 IL1B TNF
26 immune response GO:0006955 9.17 CCL2 CMA1 HLA-A IL1B IL1RN IL6

Molecular functions related to Dengue Shock Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.02 CCL2 IL1B IL1RN IL6 TNF
2 interleukin-1 receptor binding GO:0005149 8.96 IL1B IL1RN

Sources for Dengue Shock Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....